The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.
Back
Removal of REMS Programs Expands Potential of CAR T-Cell Therapy in Hematologic Malignancies
Muhammad Bilal Abid, MD, MS, FACP, MRCP, FRC, and colleagues discuss what the removal of REMS programs means for CAR T-cell therapy management.
Removal of REMS Programs Expands Potential of CAR T-Cell Therapy in Hematologic Malignancies
Episodes
All
All
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
4
The OncFive: Top Oncology Articles for the Week of 8/9
5